Stephen Strickland

Assistant Professor of Medicine

Vanderbilt University Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stephen Strickland is an Assistant Professor of Medicine at Vanderbilt University Medical Center in the United States. His research focuses on acute myeloid leukemia (AML), including clinical trials for new treatments and the implications of genetic mutations on prognosis. Recent publications highlight various aspects of AML treatment strategies and patient outcomes related to novel therapies.

Articles (11)

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Catherine Smith

Assistant Professor

UNITED STATES

View details

Dinesh Rao

Professor

UCLA

UNITED STATES

View details

Tara Lin

University of Kansas Medical Center

UNITED STATES

View details

Mark J. Levis

Johns Hopkins University

UNITED STATES

View details

Nikolai A. Podoltsev

Yale University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephen Strickland

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Secondary‐type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Isocitrate dehydrogenase inhibitor‐driven differentiation may resemble secondary graft failure in post‐allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program

A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia

The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Collaborators (5)

Catherine Smith

Dinesh Rao

Tara Lin

Mark J. Levis

Nikolai A. Podoltsev

Make your next move.